Total Returns (Price + Dividend) 
Asston Pharmaceu for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News
Announcements 
Unaudited Financial Results For The Half Year Ended 30 September 2026 With Limited Review Report.
12-Nov-2026 | Source : BSEUnaudited Financial Results for the Half Year ended 30 September 2026 with Limited Review Report.
Board Meeting Outcome for Outcome Of The Board Meeting
12-Nov-2026 | Source : BSEOutcome of the Board Meeting
Board Meeting Intimation for Intimation Of Board Meeting Scheduled To Be Held On 12Th November 2026
05-Nov-2026 | Source : BSEAsston Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2026 inter alia to consider and approve the Unaudited Financial Statements along with a limited review report for the Half-Year ended 30th September 2026
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Non Institution
None
Held by 0 Schemes
Held by 0 FIIs
Ashish Narayan Sakalkar (16.96%)
Vijay Rathee (12.06%)
49.92%
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 70.01% vs -43.21% in Mar 2025
Growth in half year ended Sep 2025 is -98.46% vs 2.63% in Mar 2025
Annual Results Snapshot (Standalone) - Mar'25
Not Applicable: The company has declared_date for only one period
Not Applicable: The company has declared_date for only one period